The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Open accessAbstract
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain. METHODS: We randomly assigned, in a 2:1 ratio, infants who had been born at a gestational age of at least 35 weeks to receive a single intramuscular injection of nirsevimab or placebo before the start of an RSV season. The primary efficacy end point was medically attended RSV-associated lower respiratory tract infection through 150 days after the injection. The secondary efficacy end point was hospitalization for RSV-associated lower respiratory tract infection through 150 days after the injection. RESULTS: A total of 1490 infants underwent randomization: 994 were assigned to the nirsevimab group and 496 to the placebo group. Medically attended RSV-associated lower respiratory tract infection occurred in 12 infants (1.2%) in the nirsevimab group and in 25 infants (5.0%) in the placebo group; these findings correspond to an efficacy of 74.5% (95% confidence interval [CI], 49.6 to 87.1; P<0.001) for nirsevimab. Hospitalization for RSV-associated lower respiratory tract infection occurred in 6 infants (0.6%) in the nirsevimab group and in 8 infants (1.6%) in the placebo group (efficacy, 62.1%; 95% CI, -8.6 to 86.8; P = 0.07). Among infants with data available to day 361, antidrug antibodies after baseline were detected in 58 of 951 (6.1%) in the nirsevimab group and in 5 of 473 (1.1%) in the placebo group. Serious adverse events were reported in 67 of 987 infants (6.8%) who received nirsevimab and in 36 of 491 infants (7.3%) who received placebo. CONCLUSIONS: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection. (Funded by MedImmune/AstraZeneca and Sanofi; MELODY ClinicalTrials.gov number, NCT03979313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773
Self-citationShi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30938-8 · Cited by 2,371
Self-citationCOMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1665 · Cited by 771
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
Griffin, M. P., Yuan, Y., Takas, T., Domachowske, J. B., Madhi, S. A., Manzoni, P., Simões, E. A. F., Esser, M. T., Khan, A. A., Dubovsky, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913556 · Cited by 762
Self-citationRespiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
Madhi, S. A., Polack, F. P., Piedra, P. A., Munoz, F. M., Trenholme, A. A., Simões, E. A. F., Swamy, G. K., Agrawal, S., Ahmed, K., August, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908380 · Cited by 418
Self-citationNATIONAL INSTITUTE OF COMMUNICABLE DISEASES
Smith, C. E. G., & Fairweather, D. V. I. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92052-1 · Cited by 384
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N. D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A., Svabek, C., McAuliffe, J. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj1928 · Cited by 362
Shi, T., Balsells, E., Wastnedge, E., Singleton, R., Rasmussen, Z. A., Zar, H. J., Rath, B. A., Madhi, S. A., Campbell, S., Vaccari, L. C., et al. (2015) · Journal of Global Health · doi:10.7189/jogh.05.020416 · Cited by 327
Self-citationDomachowske, J. B., Khan, A. A., Esser, M. T., Jensen, K., Takas, T., Villafana, T., Dubovsky, F., & Griffin, M. P. (2018) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001916 · Cited by 228
Self-citationTempia, S., Walaza, S., Bhiman, J. N., McMorrow, M., Moyes, J., Mkhencele, T., Meiring, S. T., Quan, V., Bishop, K., McAnerney, J. M., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.29.2001600 · Cited by 158
Self-citationZar, H. J., Nduru, P. M., Stadler, J. A. M., Gray, D., Barnett, W., Lesosky, M., Myer, L., & Nicol, M. P. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30251-5 · Cited by 97
Self-citationMilne, R. J., & Grimwood, K. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00534.x · Cited by 46
Respiratory illness after severe respiratory syncytial virus disease in infancy in The Gambia
Weber, M. W., Milligan, P. J., Giadom, B., et al. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70085-5 · Cited by 45
Childhood Influenza: Number Needed to Vaccinate to Prevent 1 Hospitalization or Outpatient Visit
Lewis, E. N., Griffin, M. R., Szilagyi, P. G., Zhu, Y., Edwards, K. M., & Poehling, K. A. (2007) · PEDIATRICS · doi:10.1542/peds.2007-0167 · Cited by 36
Self-citationPALMU, A. A. I., Jokinen, J., Nieminen, H. P., Rinta‐Kokko, H., Ruokokoski, E., Puumalainen, T., Moreira, M., Schuerman, L., Borys, D., & Kilpi, T. M. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.088 · Cited by 36
Number-needed-to-vaccinate calculations: Fallacies associated with exclusion of transmission
Tuite, A. R., & Fisman, D. N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.097 · Cited by 22
Cited by
Li, Y., Wang, X., Blau, D. M., Caballero, M. T., Feikin, D. R., Gill, C. J., Madhi, S. A., Omer, S. B., Simões, E. A. F., Campbell, H., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00478-0 · Cited by 1,941
Self-citationBender, R. G., Sirota, S. B., Swetschinski, L. R., Dominguez, R.-M. V., Novotney, A., Wool, E. E., Ikuta, K. S., Vongpradith, A., Rogowski, E. L. B., Doxey, M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00176-2 · Cited by 596
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Mazur, N. I., Terstappen, J., Baral, R., Bardají, A., Beutels, P., Buchholz, U. J., Cohen, C., Crowe, J. E., Cutland, C. L., Eckert, L., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00291-2 · Cited by 420
Self-citationNirsevimab for Prevention of Hospitalizations Due to RSV in Infants
Drysdale, S. B., Cathie, K., Flamein, F., Knuf, M., Collins, A. M., Hill, H. C., Kaiser, F., Cohen, R., Pinquier, D., Felter, C. T., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309189 · Cited by 382
Simões, E. A. F., Madhi, S. A., Muller, W. J., Atanasova, V., Bosheva, M., Cabañas, F., Baca Cots, M., Domachowske, J. B., Garcia-Garcia, M. L., Grantina, I., et al. (2023) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00321-2 · Cited by 318
Self-citation
Metadata
- Authors
- Hammitt, L. L., Dagan, R., Yuan, Y., Baca Cots, M., Bosheva, M., Madhi, S. A., Muller, W. J., Zar, H. J., Brooks, D., Grenham, A., Wählby Hamrén, U., Mankad, V. S., Ren, P., Takas, T., Abram, M. E., Leach, A., Griffin, M. P., & Villafana, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-03-03
- Volume
- 386
- Issue
- 9
- Pages
- 837-846
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4214852692
- Cited by
- 1,027
- References
- 16
- FWCI
- 123.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.